Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized placebo-controlled study of EGT710 in healthy adults
NL-OMON53410Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EGT710 in coronavirus disease 2019 (COVID-19), sponsored by Novartis. Started Oct 2022; status: completed.
02
Drugs
EGT710
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON53410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53410.